Alyson Thomas
Psychiatric/Mental Health · Paducah, KYNPI 1992563951
Payments from drug & device makers
Across 127 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$635
- Alkermes, Inc.$439
- AbbVie$426
- Johnson & Johnson$301
- Teva Pharmaceuticals USA, Inc.$196
- Otsuka America Pharmaceutical, Inc.$149
- plus $518 from 12 others
What the payments were for
- Food & beverage$2,652100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $635 |
| Alkermes, Inc. | 15 | $439 |
| AbbVie | 37 | $426 |
| Johnson & Johnson | 10 | $301 |
| Teva Pharmaceuticals USA, Inc. | 6 | $196 |
| Otsuka America Pharmaceutical, Inc. | 8 | $149 |
| Axsome Therapeutics, Inc. | 5 | $130 |
| Lundbeck LLC | 5 | $107 |
| Indivior Inc. | 2 | $39 |
| Collegium Pharmaceutical, Inc. | 2 | $38 |
| Seqirus USA Inc | 1 | $38 |
| Corium, LLC | 2 | $32 |
| Novo Nordisk | 2 | $30 |
| Biogen | 1 | $25 |
| Medtronic | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Exact Sciences | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$479
- ARISTADA$454
- CAPLYTA$239
- ARISTADA INITIO$113
- Austedo XR$107
How this compares
$2,664 in reported general payments places this provider in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 38 | $72,382 |
| RexultiBrexpiprazole | 11 | $15,917 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $521 |
| Duloxetine Hcl | 27 | $476 |
| Hydroxyzine Pamoate | 24 | $306 |
| Trazodone Hcl | 31 | $242 |
| Prazosin Hcl | 13 | $202 |
| Quetiapine Fumarate | 23 | $159 |
| Sertraline Hcl | 34 | $111 |
| Bupropion XlBupropion Hcl | 11 | $105 |
| Buspirone Hcl | 12 | $66 |
| Fluoxetine Hcl | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $426 | $72,38238 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $149 | $15,91711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Paducah
- Derek RatliffPaducah$14K
- Marilee BakerPaducah$8K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.